Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development.
Saved in:
| Title: | Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development. |
|---|---|
| Authors: | Feemster K; Merck & Co., Inc., Rahway, NJ 07065, USA., Hausdorff WP; Center for Vaccine Innovation and Access, PATH, 455 Massachusetts Ave NW, Washington, DC 20001, USA.; Faculty of Medicine, Université Libre de Bruxelles, 1050 Brussels, Belgium., Banniettis N; Merck & Co., Inc., Rahway, NJ 07065, USA., Platt H; Merck & Co., Inc., Rahway, NJ 07065, USA., Velentgas P; Merck & Co., Inc., Rahway, NJ 07065, USA., Esteves-Jaramillo A; Merck & Co., Inc., Rahway, NJ 07065, USA., Burton RL; SunFire Biotechnologies LLC, Birmingham, AL 35203, USA., Nahm MH; Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA., Buchwald UK; Merck & Co., Inc., Rahway, NJ 07065, USA. |
| Source: | Vaccines [Vaccines (Basel)] 2024 Aug 28; Vol. 12 (9). Date of Electronic Publication: 2024 Aug 28. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101629355 Publication Model: Electronic Cited Medium: Print ISSN: 2076-393X (Print) Linking ISSN: 2076393X NLM ISO Abbreviation: Vaccines (Basel) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
